Skip to main content

Health Stock Winners and Losers: No Pearls After Swine

Swine flu hype fails to lift widely held health stocks out of the red.

Updated from 3:45 p.m. EDT

Widely held health stocks sank into malaise Tuesday, and not even continued hype about the swine flu could lift them out of the red.

Shares of



-- among the prized truffles in the health sector Monday because it makes Relenza, an antiviral drug that could be used to combat swine flu -- fell 3.1% to $30.58.



, which


first-quarter earnings Tuesday, lowered its 2009 guidance to a range of $1.20 to $1.35 a share -- down from its previous expectations of $1.34 to $1.49 per share -- on costs related to its



acquisition. The company reaffirmed its adjusted full-year earnings of $1.85 to $1.95 per share. Pfizer stock fell 0.7% to $13.39.

Bristol-Myers Squibb


, meanwhile, also was in the red after reporting quarterly earnings. The company posted a 3%

rise in profit

based in part on sales of Plavix and Abilify, and it reaffirmed its full-year earnings guidance of $1.58 to $1.73 per share. Bristol's stock fell 4.3% to $19.65.

Johnson & Johnson


shares fell 0.4% to $50.65.



fell 1.2% to $23.17.

Eli Lilly


, among the day's few winners (albeit barely) rose 0.2% to $33.20.

Also gaining was



, which inched up 0.1% to $22.20.

In biotech news, investors were trying to make sense of what happened just before



released its latest

Provenge data

. The company's stock saw double-digit gains before

falling 45%

to $11.81 before trading was halted in advance of the data release.

Gilead Sciences


, which co-developed flu treatment Tamiflu with


, was still riding high a day after getting a boost from the swine flu effect. Shares rose 0.2% to $47.60.